Medical Xpress January 13, 2022
Riley Griffin, Angelica Peebles and Emma Court

JPMorgan Chase & Co.’s annual healthcare conference in San Francisco, which will wrap up on Thursday, has long been considered the industry’s flagship event. Executives flock to outline priorities for the year ahead, or set plans in motion behind closed doors. It’s a stage on which to announce deals or a setting for clinching them.

However, after the caused a surge in coronavirus cases, the event, now in its 40th year, was forced to go virtual for the second January in a row. While that meant less mingling over cocktails and more squinting at laptops, there’s still plenty to be divined from the health sector’s favorite crystal ball.

Here are five takeaways:

Rna is having a moment

Those...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, Market Research, Pharma / Biotech, Trends
FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder
This Biotech Startup Aims To Speed Up Drug Testing On Animals
Takeda ditches industry trade group BIO following exits by WuXi AppTec, Pfizer and UCB
Novartis, Neurocrine-Takeda, Enhertu—Fierce Pharma Asia
Xaira, Anthos, CureVac & more—Chutes & Ladders

Share This Article